ID   MRK-nu-1
AC   CVCL_1428
SY   MRK-NU-1; MRK-nu-I; Mrk-nu1; MRKnu-1; MRKnu1; MRKNU1
DR   BTO; BTO:0003679
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471641
DR   CCLE; MRKNU1_BREAST
DR   Cell_Model_Passport; SIDM00562
DR   ChEMBL-Cells; CHEMBL3308550
DR   ChEMBL-Targets; CHEMBL2366325
DR   Cosmic; 908151
DR   Cosmic-CLP; 908151
DR   DepMap; ACH-002163
DR   GDSC; 908151
DR   GEO; GSM827236
DR   GEO; GSM1670133
DR   IARC_TP53; 21516
DR   JCRB; JCRB0616
DR   JCRB; JCRB0628
DR   LINCS_LDP; LCL-1487
DR   PharmacoDB; MRKnu1_965_2019
DR   Wikidata; Q54906738
RX   CelloPub=CLPUB00083;
RX   PubMed=518958;
RX   PubMed=9290701;
RX   PubMed=15900046;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Characteristics: Established from the ascitic cells from BALB/c nu/nu mice injected intraperitoneal with the parent tumoral cells.
CC   Doubling time: ~47 hours (lot 02072012) (JCRB).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Has no TP53 mutation (PubMed=15900046).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.98%; Native American=1.19%; East Asian, North=73.82%; East Asian, South=23.21%; South Asian=0%; European, North=0.07%; European, South=0.74% (PubMed=30894373).
CC   Discontinued: JCRB; JCRB0616; probable.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 10
ST   D5S818: 13
ST   D7S820: 8,10
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_WZ71 ! MRK-nu-2
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 25
//
RX   CelloPub=CLPUB00083;
RA   Sekiguchi M., Shiroko Y., Fujii G., Sudo K., Matsuzawa A., Suzuki K.;
RT   "An ascites form of human mammary carcinoma transplantable in nude
RT   mice and isolation of two cell lines cultured in vitro.";
RL   Proc. Jpn. Cancer Assoc. 38:139-139(1979).
//
RX   PubMed=518958;
RA   Sekiguchi M., Sudo K., Suzuki K., Matsuzawa A., Fujii G.;
RT   "An ascites form of human mammary carcinoma transplantable in nude
RT   mice.";
RL   Biomedicine 30:245-249(1979).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//